Ensign Peak Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.31M | Hold |
36,071
| – | – | ﹤0.01% | 1091 |
|
|
2025
Q1 | $1.31M | Buy |
36,071
+6,850
| +23% | +$248K | ﹤0.01% | 1107 |
|
|
2024
Q4 | $1.23M | Buy |
29,221
+100
| +0.3% | +$4.21K | ﹤0.01% | 1195 |
|
|
2024
Q3 | $1.62M | Hold |
29,121
| – | – | ﹤0.01% | 1046 |
|
|
2024
Q2 | $1.2M | Hold |
29,121
| – | – | ﹤0.01% | 1172 |
|
|
2024
Q1 | $1.36M | Sell |
29,121
-1,469
| -5% | -$68.6K | ﹤0.01% | 1129 |
|
|
2023
Q4 | $1.46M | Hold |
30,590
| – | – | ﹤0.01% | 1103 |
|
|
2023
Q3 | $1.09M | Hold |
30,590
| – | – | ﹤0.01% | 1132 |
|
|
2023
Q2 | $1.41M | Buy |
30,590
+450
| +1% | +$20.8K | ﹤0.01% | 1015 |
|
|
2023
Q1 | $1.21M | Hold |
30,140
| – | – | ﹤0.01% | 1091 |
|
|
2022
Q4 | $1.4M | Sell |
30,140
-83,849
| -74% | -$3.88M | ﹤0.01% | 952 |
|
|
2022
Q3 | $4.72M | Buy |
113,989
+28,675
| +34% | +$1.19M | 0.01% | 534 |
|
|
2022
Q2 | $5.09M | Buy |
85,314
+70,614
| +480% | +$4.21M | 0.01% | 533 |
|
|
2022
Q1 | $1.07M | Hold |
14,700
| – | – | ﹤0.01% | 1157 |
|
|
2021
Q4 | $1.24M | Buy |
+14,700
| New | +$1.24M | ﹤0.01% | 1170 |
|